New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Outcomes of Liver Transplantation in Patients with Preexisting Coronary Artery Disease.
Outcomes of Liver Transplantation in Patients with Preexisting Coronary Artery Disease. Transplantation Reznicek, E., Sasaki, K., Montane, B., Sims, A., Beard, J., Fares, M., Sharma, V., Cywinski, J., Quintini, C., Aucejo, F. N., Eghtesad, B., Miller, C. M., Menon, K. V. 2022Abstract
Advances in surgical and medical technology over the years has made liver transplantation possible for older and higher risk patients. Despite rigorous preoperative cardiac testing, cardiovascular events remain a major cause of death after orthotopic liver transplantation (OLT). However, there are little data on the outcomes of OLT in patients with preexisting coronary artery disease (CAD). This study aimed to compare all-cause and cardiovascular mortality of patients with and without history of CAD undergoing OLT.Six hundred ninety-three adult patients with cirrhosis underwent liver transplantation between July 2013 and December 2018 (female n?=?243, male n?=?450; median age 59).During the study period of 5 y (median follow-up, 24.1 mo), 92 of 693 patients (13.3%) died. All-cause mortality in the CAD group was significantly higher than in the non-CAD group (26.7% versus 9.6%; P<0.01). Cardiovascular events accounted for 52.5% of deaths (n?=?21) in patients with CAD compared with 36.5% (n?=?19) in non-CAD patients. At 6 mo, patients with combined nonalcoholic steatohepatitis (NASH)/CAD had significantly worse survival than those with CAD or NASH alone (P<0.01). After 6 mo, patients with CAD alone had similar survival to those with combined NASH/CAD.Patients with preexisting CAD before liver transplantation are at higher risk of death from any cause, specifically cardiovascular-related death. This risk increases with coexisting NASH. The presence of NASH and CAD at the time of liver transplant should prompt the initiation of aggressive risk factor modification for patients with CAD.
View details for DOI 10.1097/TP.0000000000004402
View details for PubMedID 36397734